Full Text | PDF

Share on facebook Share on tweeters Share on linkedin Share on googleplus

Theranostics 2024; 14(1):392-405. doi:10.7150/thno.87243 This issue Cite

Research Paper

Imaging diagnosis and efficacy monitoring by [89Zr]Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies

Huihui He1†, Xiaowei Qi2†, Haitian Fu1†, Jianfeng Xu3, Qihuang Zheng4, Liping Chen1, Yu Zhang1, Haiying Hua5, Wenhuan Xu5, Zhenyu Xu5, Xiaoping Chen5, Qingjun You6, Jianguo Lin7, Gang Huang8*✉, Yong Mao5*✉, Chunjing Yu1*✉

1. Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University; Wuxi, China.
2. Department of Pathology, Affiliated Hospital of Jiangnan University; Wuxi, China.
3. Dongcheng AMS Pharmaceutical Co., Ltd.; Nanjing, China.
4. Center of Radiological Imaging, College of Medicine, Indiana University, Indiana, USA.
5. Department of Oncology, Affiliated Hospital of Jiangnan University; Wuxi, China.
6. Institute of Oncology, Affiliated Hospital of Jiangnan University; Wuxi, China.
7. NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine; Jiangsu Institute of Nuclear Medicine, Wuxi, China.
8. Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences; Shanghai, China.
*These authors contributed equally to this work.
†These authors contributed equally to this work.

✉ Corresponding authors: Chunjing Yu, Email: ycjwxd1978edu.cn; Yong Mao, Email: mydoctorwxcom; Gang Huang, Email: huanggangedu.cn.

Citation:
He H, Qi X, Fu H, Xu J, Zheng Q, Chen L, Zhang Y, Hua H, Xu W, Xu Z, Chen X, You Q, Lin J, Huang G, Mao Y, Yu C. Imaging diagnosis and efficacy monitoring by [89Zr]Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies. Theranostics 2024; 14(1):392-405. doi:10.7150/thno.87243. https://www.thno.org/v14p0392.htm
Other styles

File import instruction

Abstract

Graphic abstract

Rationale: Although programmed death-ligand 1 (PD-L1) inhibitors have achieved efficacy in cancer therapy, their response rate is low. Differences in the prognosis of patients with cancer under anti-PD-L1 treatment are related to the PD-L1 level in tumors. Accurate PD-L1 detection can optimize the accuracy of tumor immunotherapy and avoid ineffective clinical diagnosis and treatments.

Methods: We investigated the imaging efficiency and therapy monitoring capacity of [89Zr]Zr-DFO-KN035 immunoPET for tumors. We labeled the monodomain anti-PD-L1 antibody KN035 with the radionuclide zirconium-89 and used this tracer for PET imaging. [89Zr]Zr-DFO-KN035 uptakes in patients with PD-L1-positive tumors, including primary and metastatic tumors, as well as in normal tissues, were comparatively assessed by using positron emission tomography/computed tomography imaging.

Results: In PD-L1-positive patients, [89Zr]Zr-DFO-KN035 was sensitive in tumor-targeting imaging and could detect multiple metastatic foci, including multiple bone metastases (tumor-to-muscle ratios of 7.102 and 6.118 at 55 and 120 h, respectively) and lymph-node metastases (tumor-to-muscle ratios of 11.346 and 6.542 at 55 and 120 h, respectively). The needed radioactive dose of [89Zr]Zr-DFO-KN035 (55.5-92.5 MBq) used in this study was considerably lower than that of [18F]FDG (370-555 MBq). [89Zr]Zr-DFO-KN035 monitored and predicted the site of adverse reactions in antitumor immunotherapy. Moreover, after antitumor treatment, [89Zr]Zr-DFO-KN035 enabled observational imaging for therapeutic efficacy evaluation, which can help predict patient prognosis.

Conclusion: [89Zr]Zr-DFO-KN035 can be used for the diagnosis and therapy monitoring of PD-L1-positive tumors and provide noninvasive and comprehensive observations for tumor diagnostic imaging, prognosis prediction, and efficacy evaluation.

Keywords: PD-L1 antibody, tumor immunotherapy, efficacy monitoring, molecular imaging, PET

Citation styles

APA
He, H., Qi, X., Fu, H., Xu, J., Zheng, Q., Chen, L., Zhang, Y., Hua, H., Xu, W., Xu, Z., Chen, X., You, Q., Lin, J., Huang, G., Mao, Y., Yu, C. (2024). Imaging diagnosis and efficacy monitoring by [89Zr]Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies. Theranostics, 14(1), 392-405. https://doi.org/10.7150/thno.87243.

ACS
He, H.; Qi, X.; Fu, H.; Xu, J.; Zheng, Q.; Chen, L.; Zhang, Y.; Hua, H.; Xu, W.; Xu, Z.; Chen, X.; You, Q.; Lin, J.; Huang, G.; Mao, Y.; Yu, C. Imaging diagnosis and efficacy monitoring by [89Zr]Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies. Theranostics 2024, 14 (1), 392-405. DOI: 10.7150/thno.87243.

NLM
He H, Qi X, Fu H, Xu J, Zheng Q, Chen L, Zhang Y, Hua H, Xu W, Xu Z, Chen X, You Q, Lin J, Huang G, Mao Y, Yu C. Imaging diagnosis and efficacy monitoring by [89Zr]Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies. Theranostics 2024; 14(1):392-405. doi:10.7150/thno.87243. https://www.thno.org/v14p0392.htm

CSE
He H, Qi X, Fu H, Xu J, Zheng Q, Chen L, Zhang Y, Hua H, Xu W, Xu Z, Chen X, You Q, Lin J, Huang G, Mao Y, Yu C. 2024. Imaging diagnosis and efficacy monitoring by [89Zr]Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies. Theranostics. 14(1):392-405.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use